BioCentury | Oct 23, 2000
Company News

Labopharm management update

Labopharm Inc. (TSE:DDS), Montreal, Quebec Business: Drug delivery Promoted: Vincent Lenaerts to CSO while remaining VP of R&D Hired: Allan Mandelzys as VP of business development, formerly director of business development at Allelix BioPharmaceuticals Inc.;...
BioCentury | Aug 2, 1999
Company News

Neurochem, Resolution Pharmaceuticals deal

...Resolution’s radioimaging technology. Both companies will conduct lead molecule development. Neurochem Inc. , Saint-Laurent, Quebec Resolution Pharmaceuticals Inc....
BioCentury | Jan 2, 1996
Clinical News

RP128 peptide-based radiopharmaceutical: Completed a European Phase I trial

Resolution Pharmaceuticals Inc. , Mississauga, Ontario Product: RP128 peptide-based radiopharmaceutical Indication: Imaging of inflammation Status: Resolution, a joint venture between Allelix Biopharmaceuticals Inc. (AXB) and Nordion International, completed a European Phase I trial in normal volunteers....
BioCentury | Oct 23, 1995
Clinical News

RP128: The joint venture between Allelix Biopharmaceuticals (TSE:AXB) and Nordion International began a Phase I trial in normal volunteers to assess safety and

Resolution Pharmaceuticals Inc. , Toronto Product: RP128, peptide-based radiopharmaceutical Indication: Imaging inflammation Status: The joint venture between Allelix Biopharmaceuticals (TSE:AXB) and Nordion International began a Phase I trial in normal volunteers to assess safety and dosimetry....
Items per page:
1 - 4 of 4
BioCentury | Oct 23, 2000
Company News

Labopharm management update

Labopharm Inc. (TSE:DDS), Montreal, Quebec Business: Drug delivery Promoted: Vincent Lenaerts to CSO while remaining VP of R&D Hired: Allan Mandelzys as VP of business development, formerly director of business development at Allelix BioPharmaceuticals Inc.;...
BioCentury | Aug 2, 1999
Company News

Neurochem, Resolution Pharmaceuticals deal

...Resolution’s radioimaging technology. Both companies will conduct lead molecule development. Neurochem Inc. , Saint-Laurent, Quebec Resolution Pharmaceuticals Inc....
BioCentury | Jan 2, 1996
Clinical News

RP128 peptide-based radiopharmaceutical: Completed a European Phase I trial

Resolution Pharmaceuticals Inc. , Mississauga, Ontario Product: RP128 peptide-based radiopharmaceutical Indication: Imaging of inflammation Status: Resolution, a joint venture between Allelix Biopharmaceuticals Inc. (AXB) and Nordion International, completed a European Phase I trial in normal volunteers....
BioCentury | Oct 23, 1995
Clinical News

RP128: The joint venture between Allelix Biopharmaceuticals (TSE:AXB) and Nordion International began a Phase I trial in normal volunteers to assess safety and

Resolution Pharmaceuticals Inc. , Toronto Product: RP128, peptide-based radiopharmaceutical Indication: Imaging inflammation Status: The joint venture between Allelix Biopharmaceuticals (TSE:AXB) and Nordion International began a Phase I trial in normal volunteers to assess safety and dosimetry....
Items per page:
1 - 4 of 4